Last updated: November 9, 2023
Sponsor: Kringle Pharma, Inc.
Overall Status: Active - Recruiting
Phase
3
Condition
N/ATreatment
Placebo
KP-100LI
Clinical Study ID
NCT05627648
KP-100-FD001
Ages 18-75 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- 18 years to 75 years
- Presence of bilateral vocal fold scar or sulcus diagnosed
- No other vocal lesion or vocal movement disorder
- Voice Handicap Index-10 (VHI-10) score of 11 or higher
- No laryngoplasty, collagen or lipid infusion to vocal cord, removal scar, fascialgraft, or administration of steroid or hyaluronic acid to vocal cord
Exclusion
Exclusion Criteria:
- No movement disorders of the vocal fold including paralysis
- Airway disease caused by burn
- History of malignant tumor
- History of allergy to local anesthesia agent
- With impaired coagulation-fibrinolysis, or taking anticoagulant or antiplatelet drugs
- Serious concomitant disease
- Pregnant (including suspected), nursing, wishing to become pregnant, or unable toprevent conception during the trial period using contraceptive methods
Study Design
Total Participants: 62
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 3
Study Start date:
November 24, 2022
Estimated Completion Date:
November 30, 2025
Connect with a study center
Kurume University Hospital
Kurume, Fukuoka
JapanActive - Recruiting
University Hospital Kyoto Prefectural University of Medicine
Kamigyo-ku, Kyoto 602-8566
JapanActive - Recruiting
Tohoku University Hospital
Sendai, Miyagi
JapanActive - Recruiting
Kawasaki Medical School Hospital
Kurashiki, Okayama
JapanActive - Recruiting
Nihon University Hospital
Chiyoda-ku, Tokyo
JapanActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.